Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pretomanid

FDA-approved product (tablet, oral), marketed as Pretomanid.

Registered studies
49
Lab records
57
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pretomanid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Drug-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK08; FDA class Antimycobacterial

Repurposing investigation

Pretomanid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 52 of 57 lab records
Open Pretomanid in ChEMBL Registered studies below
Show the 57 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pretomanid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • B-PaLMZ for TB Meningitis

    NCT07227779 · start 2026-07-28

    Registered record
    Registry ID
    NCT07227779
    Conditions
    Tuberculous Meningitis; HIV; Meningitis; TB - Tuberculosis
    Interventions
    BPaLMZ Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-28
    Completion
    2030-09-30
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculous Meningitis; HIV; Meningitis; TB - Tuberculosis
    InterventionBPaLMZ Regimen
    PhasePhase 2
    Registry statusRecruiting

  • Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis

    NCT07773610 · start 2026-07-23

    Registered record
    Registry ID
    NCT07773610
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    TBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg; HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination); Quabodepistat (Q) 30 mg; Ganfeborole 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-23
    Completion
    2027-12-30
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionTBAJ-587 50 mg; Pretomanid 200mg; Linezolid 600Mg Tab; BTZ-043 250 mg or 500 mg +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB

    NCT07672405 · start 2026-07-09

    Registered record
    Registry ID
    NCT07672405
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    sorfequiline; Pretomanid; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-07-09
    Completion
    2028-06-24
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    Interventionsorfequiline; Pretomanid; Linezolid
    PhasePhase 2
    Registry statusRecruiting

  • Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

    NCT07517445 · start 2026-04-17

    Registered record
    Registry ID
    NCT07517445
    Conditions
    Drug Susceptible Pulmonary Tuberculosis
    Interventions
    Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Nicotinamide (NAM)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2026-04-17
    Completion
    2027-06-14
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Susceptible Pulmonary Tuberculosis
    InterventionBedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Bedaquiline, pretomanid, linezolid; Nicotinamide (NAM)
    PhasePhase 2
    Registry statusSuspended

  • Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

    NCT07525427 · start 2026-04-14

    Registered record
    Registry ID
    NCT07525427
    Conditions
    Drug Susceptible Pulmonary Tuberculosis
    Interventions
    Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-04-14
    Completion
    2026-11-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Susceptible Pulmonary Tuberculosis
    InterventionBedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09; Bedaquiline, pretomanid and TBD09 +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

    NCT07209761 · start 2025-10-16

    Registered record
    Registry ID
    NCT07209761
    Conditions
    Pulmonary Tuberculosis
    Interventions
    BPaQM; BPaLM; BPaQ; BPaL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-10-16
    Completion
    2028-09-29
    Enrolment
    532

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBPaQM; BPaLM; BPaQ; BPaL
    PhasePhase 3
    Registry statusRecruiting

  • Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

    NCT06441006 · start 2025-10-03

    Registered record
    Registry ID
    NCT06441006
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
    Interventions
    Bedaquiline; Linezolid; Pretomanid; Moxifloxacin; Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-10-03
    Completion
    2031-08
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis, Multidrug-Resistant; Tuberculosis, MDR
    InterventionBedaquiline; Linezolid; Pretomanid; Moxifloxacin +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis

    NCT07191834 · start 2025-09-30

    Registered record
    Registry ID
    NCT07191834
    Conditions
    Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis; Type 2 Diabetes Mellitus (T2DM); Pretomanid
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-09-30
    Completion
    2027-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis; Type 2 Diabetes Mellitus (T2DM); Pretomanid
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

    NCT07126639 · start 2025-09-01

    Registered record
    Registry ID
    NCT07126639
    Conditions
    Efficacy and Safety
    Interventions
    bedaquiline; Pretomanid (Pa); linezolid; Moxifloxacin (M); Delamanid (D); Levofloxacin; clofazimine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2028-09-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEfficacy and Safety
    Interventionbedaquiline; Pretomanid (Pa); linezolid; Moxifloxacin (M) +3 more
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A PAN-USR TB Multi-Center Trial

    NCT06905522 · start 2025-06-18

    Registered record
    Registry ID
    NCT06905522
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Bedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z); Isoniazid (H); Rifampicin (R); Ethambutol (E); Moxifloxacin (M); Pretomanid (Pa)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-18
    Completion
    2029-12
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionBedaquiline (B); Sitafloxacin (S); Linezolid (L); Pyrazinamide (Z) +5 more
    PhasePhase 3
    Registry statusRecruiting

  • Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

    NCT06192160 · start 2025-03-11

    Registered record
    Registry ID
    NCT06192160
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Isoniazid; Rifampicin; Pyrazinamide; Ethambutol; Bedaquiline; Pretomanid; Linezolid; TBI-223; Sutezolid; TBI-223; Sutezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-11
    Completion
    2027-08-11
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionIsoniazid; Rifampicin; Pyrazinamide; Ethambutol +7 more
    PhasePhase 2
    Registry statusRecruiting

  • Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

    NCT03896750 · start 2024-04-17

    Registered record
    Registry ID
    NCT03896750
    Conditions
    Renal Impairment; Tuberculosis
    Interventions
    PA-824
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-04-17
    Completion
    2024-10-28
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment; Tuberculosis
    InterventionPA-824
    PhasePhase 1
    Registry statusCompleted

  • Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

    NCT06114628 · start 2024-01-09

    Registered record
    Registry ID
    NCT06114628
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Ganfeborole; BTZ-043; Bedaquiline (B); Delamanid (D); Pretomanid (Pa); Moxifloxacin (M); Linezolid (L); Pyrazinamide (Z); Rifampicin (R); Isoniazid (H); Ethambutol (E); Delpazolid (DZD); Quabodepistat (Q)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-09
    Completion
    2027-08-11
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionGanfeborole; BTZ-043; Bedaquiline (B); Delamanid (D) +9 more
    PhasePhase 2
    Registry statusRecruiting

  • Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

    NCT06058299 · start 2023-10-31

    Registered record
    Registry ID
    NCT06058299
    Conditions
    Pulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis
    Interventions
    sorfequiline; Pretomanid; Linezolid; Bedaquiline; HRZE; HR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-10-31
    Completion
    2027-02
    Enrolment
    309

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis
    Interventionsorfequiline; Pretomanid; Linezolid; Bedaquiline +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

    NCT05586230 · start 2023-10-03

    Registered record
    Registry ID
    NCT05586230
    Conditions
    Tuberculosis; Rifampicin Resistant Tuberculosis
    Interventions
    Pretomanid; Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-10-03
    Completion
    2026-04-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Rifampicin Resistant Tuberculosis
    InterventionPretomanid; Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)
    PhasePhase 1
    Registry statusCompleted